Seattle biotech firm Athira Pharma will pay $4M to settle allegations related to research misconduct
Seattle-area biotech company Athira Pharma agreed to pay $4.07 million to settle allegations that it violated the False Claims Act by failing to disclose research misconduct to federal agencies in grant applications and reports.
Bothell's Athira Pharma to pay $4M to settle falsified research claims
Bothell-based biopharmaceutical company Athira Pharma Inc. (Nasdaq: ATHA) is paying a $4.1 million fine due to allegations it used doctored research to land a National Institutes of Health grant.
Bothell's Athira Pharma Settles for Over $4 Million After Allegations of Research Misconduct
A biopharmaceutical company, Athira Pharma, settled for $4.068 million over allegations of research misconduct.
Athira Pharma to pay $4M to settle False Claims Act allegations
Athira Pharma (ATHA) agreed to pay $4,068,698 to resolve allegations that it violated the False Claims Act by failing to report allegations of
Bothell pharma company to pay $4 million over falsified research claims
A pharmaceutical company in Bothell has agreed to pay $4,068,698 to settle allegations it used falsified research to obtain grants from the National Institutes of Health (NIH), according to the Department of Justice.
Athira to pay $4M to resolve research misconduct allegations
Stressing the importance of integrity in taxpayer-funded biomedical research, the U.S. Department of Justice reported that Athira Pharma Inc. has agreed to pay more than $4 million to resolve False Claims Act allegations that it failed to report potential research misconduct to the NIH and the Department of Health and Human Services’ Office of Research Integrity in grant applications and progress reports.
Yahoo Finance1d
Athira Pharma, Inc. (ATHA)
BOTHELL, Wash., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health ...
Morningstar2mon
Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates
BOTHELL, Wash., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health ...
Athira Pharma, Inc. (NASDAQ:ATHA) CEO Mark James Litton Sells 25,107 Shares
CEO Mark James Litton sold 25,107 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $0.56, for a total transaction of $14,059.92. Following the ...
Investing27d
Athira Pharma's SWOT analysis: stock faces challenges after trial setback
Athira Pharma Inc. (NASDAQ:ATHA), a biopharmaceutical company focused on developing therapies for neurodegenerative diseases, has experienced significant challenges in recent months. With a ...
Morningstar6d
Athira Pharma Inc Ordinary Shares
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...